Literature DB >> 31170892

Hepatic Myoepithelial Carcinoma in a Dog: Immunohistochemical Comparison With Other Canine Hepatic Carcinomas.

Yuka Tsuji1, Mizuki Kuramochi1, Takeshi Izawa1, Hideo Akiyoshi2, Jyoji Yamate1, Mitsuru Kuwamura1.   

Abstract

An 11-year-old female miniature Dachshund dog presented with a solid, soft, gray mass on the hepatic lateral left lobe. Histologically, the mass consisted of neoplastic proliferation of cells with round nuclei and eosinophilic and vacuolated cytoplasm arranged in alveolar, trabecular, and solid patterns. Immunohistochemically, the neoplastic cells were positive for pancytokeratin (CK AE1/AE3), CK5, CK14, vimentin, Sox9, and myoepithelial markers (α-smooth muscle actin, p63, and calponin). The morphological and immunohistochemical findings indicated a diagnosis of myoepithelial carcinoma. We conducted immunohistochemical studies on other representative canine hepatic tumors. Although the myoepithelial phenotype was not observed in the hepatocellular carcinoma, some tumor cells in cholangiocarcinoma showed immunohistochemical features of myoepithelium, suggesting that some neoplastic cells in cholangiocarcinoma may have the potential to differentiate into myoepithelial cells. To our knowledge, this is the first report in veterinary medicine of a hepatic carcinoma with a myoepithelial phenotype.

Entities:  

Keywords:  cholangiocarcinoma; dog; hepatocellular carcinoma; histopathology; immunohistochemistry; liver; myoepithelial cells

Mesh:

Substances:

Year:  2019        PMID: 31170892     DOI: 10.1177/0300985819854439

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  2 in total

1.  The Activity Screening of Hmong Herbs Caesalpiniaminax and an Antitumor Effect Study.

Authors:  Cong Huang; Minghong Dong; Jinfang Luo; Haibing Qian; Jingjie Zhang; Yongqi Huang
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-26       Impact factor: 2.629

2.  Activity Screening of the Herb Caesalpinia sappan and an Analysis of Its Antitumor Effects.

Authors:  Yuan Li; Minghong Dong; Zijun Wu; Yongqi Huang; Haibing Qian; Cong Huang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-25       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.